BROOKINGS, S.D. — Medgene, a South Dakota-based animal health company, will be conducting a study to test a vaccine produced by its USDA-approved platform technology against a variant of avian influenza.
Highly pathogenic avian influenza (HPAI, or bird flu) has become widespread among wild birds and created significant economic loss to the U.S. poultry industry. The H5N1 HPAI variant is being described as the largest bird pandemic recorded, resulting in the destruction of millions of commercially raised geese, turkeys and chickens, as well as killing untold numbers of wild birds. While the total economic impact of HPAI. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
